Xeris Biopharma Holdings, Inc.
XERS
Updated: 24/09/2026, 03:56:12
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
No summaries found.
- Share price
- $8.66
- Market cap
- $1.50B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- John Shannon
- Employees
- 435
- IPO date
- 21/06/2018
- Beta
- 0.85
- Last dividend
- $0.00
- Day range
- $8.46 – $9.20
- 52-week range
- $5.25 – $10.08
- 1-day performance
- -0.80%
- 1-year performance
- 64.95%
- Current drawdown (1Y)
- -14.09%
- CIK
- 0001867096
- CUSIP
- 98422E103
- ISIN
- US98422E1038
- Created
- 07/12/2025, 15:09:32
- Last update
- 24/09/2026, 03:56:12
Track Xeris Biopharma Holdings, Inc. with an AI analyst
See which prediction-market events move XERS, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS®
Business Wire • STOCK • 11/06/2026, 18:39:00
Xeris Looks Ridiculously Cheap If Growth Forecasts Are Even Halfway Right
Seeking Alpha • STOCK • 31/05/2026, 01:31:08
Xeris Biopharma Q1 Earnings Call Highlights
MarketBeat • STOCK • 09/05/2026, 06:07:26
Xeris Biopharma Holdings, Inc. (XERS) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 07/05/2026, 15:41:22
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Business Wire • STOCK • 03/04/2026, 18:15:00
Xeris Biopharma Holdings, Inc. (XERS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Seeking Alpha • STOCK • 11/03/2026, 14:32:18
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Reports Record Financial Performance
Market Data • Market Data • 02/03/2026, 14:06:01
Xeris Biopharma Holdings, Inc. (XERS) Q4 2025 Earnings Call Transcript
Seeking Alpha • STOCK • 02/03/2026, 11:57:49
Xeris Biopharma (XERS) Q4 Earnings and Revenues Surpass Estimates
Zacks Investment Research • STOCK • 02/03/2026, 10:16:12
Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit
Business Wire • STOCK • 26/02/2026, 18:55:00
Unlocking Q4 Potential of Xeris Biopharma (XERS): Exploring Wall Street Estimates for Key Metrics
Zacks Investment Research • STOCK • 26/02/2026, 11:21:16
Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026
Business Wire • STOCK • 17/02/2026, 08:30:00